Verona Pharma Plc ADR (VRNA)

Feb 18, 2025, 6:00 AM EST - 4 days ago

Verona Pharma Announces March 2025 Investor Conference Participation

Feb 13, 2025, 6:00 AM EST - 9 days ago

Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update

Jan 8, 2025, 1:45 PM EST - 6 weeks ago

Verona Pharma's Ohtuvayre Defies Expectations In Q4, But Stock Alpha May Now Be Limited

Jan 7, 2025, 6:00 AM EST - 6 weeks ago

Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights

Nov 19, 2024, 2:00 AM EST - 3 months ago

Verona Pharma Announces December 2024 Investor Conference Participation

Nov 9, 2024, 8:23 AM EST - 3 months ago

Caligan picks up a stake in Verona Pharma, seeing an opportunity to generate more value

Nov 5, 2024, 2:00 AM EST - 3 months ago

Verona Pharma to Present at Jefferies London Healthcare Conference

Nov 4, 2024, 11:47 AM EST - 3 months ago

Verona Pharma plc (VRNA) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 2:00 AM EST - 3 months ago

Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 21, 2024, 2:00 AM EDT - 4 months ago

Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Oct 8, 2024, 5:00 AM EDT - 4 months ago

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

ENTO OCS ONCO

Sep 30, 2024, 2:00 AM EDT - 5 months ago

Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024

Sep 14, 2024, 4:20 AM EDT - 5 months ago

Verona Pharma's Ohtuvayre Set To Unlock Significant Value In COPD Care

Sep 5, 2024, 2:00 AM EDT - 6 months ago

Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024

Aug 14, 2024, 8:35 AM EDT - 6 months ago

Top 3 Health Care Stocks That May Crash In August

CAH CPRX

Aug 8, 2024, 1:15 PM EDT - 7 months ago

Verona Pharma plc (VRNA) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 2:00 AM EDT - 7 months ago

Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 30, 2024, 10:13 AM EDT - 7 months ago

Top 3 Health Care Stocks You May Want To Dump This Quarter

CPRX VRDN

Jul 30, 2024, 2:00 AM EDT - 7 months ago

Verona Pharma to Present at 44th Annual Canaccord Growth Conference

Jul 25, 2024, 2:00 AM EDT - 7 months ago

Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Jun 30, 2024, 9:00 AM EDT - 8 months ago

Verona Pharma Is Launching Ohtuvayre, Although There Will Be Competition

Jun 27, 2024, 9:49 AM EDT - 8 months ago

First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product

Jun 27, 2024, 9:03 AM EDT - 8 months ago

Verona Pharma's inhaled COPD therapy to be priced at $2,950 per month

Jun 26, 2024, 5:13 PM EDT - 8 months ago

US FDA approves Verona Pharma's therapy for 'smoker's lungs'

Jun 26, 2024, 4:57 PM EDT - 8 months ago

Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)

Jun 24, 2024, 4:51 AM EDT - 8 months ago

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More

MRK NTLA ARWR XFOR

Jun 20, 2024, 12:45 PM EDT - 8 months ago

Verona Pharma: Next Week's PDUFA Date Ought To Provide An Upside Catalyst

May 9, 2024, 12:31 PM EDT - 10 months ago

Verona Pharma plc (VRNA) Q1 2024 Earnings Call Transcript

May 9, 2024, 7:15 AM EDT - 10 months ago

Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 7:00 AM EDT - 10 months ago

Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS

May 2, 2024, 2:00 AM EDT - 10 months ago

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024

Apr 25, 2024, 2:00 AM EDT - 10 months ago

Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update

Mar 4, 2024, 2:00 AM EST - 1 year ago

Andrew Fisher Joins Verona Pharma as General Counsel

Feb 29, 2024, 12:36 PM EST - 1 year ago

Verona Pharma plc (VRNA) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 2:00 AM EST - 1 year ago

Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Feb 15, 2024, 2:00 AM EST - 1 year ago

Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

Feb 1, 2024, 2:00 AM EST - 1 year ago

Michael Austwick Joins Verona Pharma as Non-Executive Director

Jan 3, 2024, 2:00 AM EST - 1 year ago

Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference

Jan 2, 2024, 2:00 AM EST - 1 year ago

Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital

Nov 18, 2023, 2:54 AM EST - 1 year ago

Verona Pharma's Ensifentrine: Potentially A New Era In Respiratory Disease Treatment

Nov 17, 2023, 2:00 AM EST - 1 year ago

Verona Pharma's President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award

Nov 8, 2023, 2:00 AM EST - 1 year ago

Verona Pharma Announces November 2023 Investor Conference Participation

Nov 4, 2023, 11:58 AM EDT - 1 year ago

Verona Pharma plc (VRNA) Q3 2023 Earnings Call Transcript

Nov 2, 2023, 3:04 AM EDT - 1 year ago

Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Oct 19, 2023, 2:00 AM EDT - 1 year ago

Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate Update

Oct 6, 2023, 2:00 AM EDT - 1 year ago

Verona Pharma to Host Investor Update on Commercialization Preparation for Ensifentrine on October 18, 2023

Oct 3, 2023, 2:00 AM EDT - 1 year ago

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023

Sep 11, 2023, 2:00 AM EDT - 1 year ago

Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD

Sep 6, 2023, 2:00 AM EDT - 1 year ago

Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023

Sep 4, 2023, 11:45 PM EDT - 1 year ago

Verona Pharma: De-Risked COPD Biotech Play, Approval Likely Coming Soon